2023 World Conference on Lung Cancer (Posters)-EP07.05. Real-World Outcomes of Adjuvant Cisplatin/Vinorelbine vs Cisplatin/Pemetrexed in Resected Non-Squamous NSCLC

EP07.05. Real-World Outcomes of Adjuvant Cisplatin/Vinorelbine vs Cisplatin/Pemetrexed in Resected Non-Squamous NSCLC - PDF(Abstract)

Back to course

Pdf Summary

This study examined the real-world outcomes of adjuvant cisplatin/vinorelbine (Cis/Vin) compared to cisplatin/pemetrexed (Cis/Pem) in resected non-squamous non-small cell lung cancer (NSCLC) patients. The researchers conducted a retrospective analysis on patients receiving either Cis/Vin or Cis/Pem between January 2019 and December 2022. They found that the Cis/Pem group had fewer treatment visits per patient, higher chemotherapy completion rates, and higher average dose intensities compared to the Cis/Vin group. The most common toxicities experienced by all groups were fatigue, constipation, and nausea. The addition of granulocyte colony-stimulating factor (GCSF) to the Cis/Vin group reduced the rate of neutropenia but did not eliminate it completely. The Cis/Pem group had no grade 3-4 toxicities or hematological toxicities and experienced fewer hospitalizations. Overall, the study confirmed that Cis/Pem is a more tolerable adjuvant regimen with less severe toxicities, improved completion rates, higher dose intensity, and reduced hospital visits compared to Cis/Vin. The researchers recommend the continued use of Cis/Pem as adjuvant chemotherapy for non-squamous NSCLC patients in the post-Covid era.

Asset Subtitle

Samantha Low

Meta Tag

Speaker Samantha Low

Topic Early-Stage NSCLC: Pushing the Boundaries

Keywords

adjuvant cisplatin/vinorelbine

adjuvant cisplatin/pemetrexed

resected non-squamous non-small cell lung cancer

chemotherapy completion rates

average dose intensities

toxicities

neutropenia

hospitalizations

tolerable adjuvant regimen

post-Covid era